Caroline Y. Kuo

Caroline Y. Kuo

Auto-generated profile, based on publicly available information

Caroline Y. Kuo

University of California, Los Angeles 1 Division of Allergy, Immunology & Rheumatology, Department of Pediatrics Los Angeles, CA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Cell Reports
Verified
Journal Article
Open access
CKCaroline Y. Kuo
Caroline Y. Kuo
JLJoseph D. Long
Joseph D. Long
BCBeatriz Campo-Fernandez
Beatriz Campo-Fernandez
SOSatiro de Oliveira
Satiro de Oliveira
ACAaron R. Cooper
Aaron R. Cooper
DKDonald B. Kohn
Donald B. Kohn
X-linked hyper-immunoglobulin M (hyper-IgM) syndrome (XHIM) is a primary immunodeficiency due to mutations in CD40 ligand that affect immunoglobulin class-switch recombination and somatic hypermutation. The disease is amenable to gene therapy using retroviral vectors, but dysregulated gene expression results in abnormal lymphoproliferation in mouse models, highlighting the need for alternative strategies. Here, we demonstrate the ability of both the transcription activator-like effector nuclease (TALEN) and clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR/Cas9) platforms to efficiently drive integration of a normal copy of the CD40L cDNA delivered by Adeno-Associated Virus. Site-specific insertion of the donor sequence downstream of the endogenous CD40L promoter maintained physiologic expression of CD40L while overriding all reported downstream mutations. High levels of gene modification were achieved in primary human hematopoietic stem cells (HSCs), as well as in cell lines and XHIM-patient-derived T cells. Notably, gene-corrected HSCs engrafted in immunodeficient mice at clinically relevant frequencies. These studies provide the foundation for a permanent curative therapy in XHIM.

19 September 2018 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
FCFabiana Csukasi
Fabiana Csukasi
IDIvan Duran
Ivan Duran
MBMaya Barad
Maya Barad
TBTomas Barta
Tomas Barta
IGIva Gudernova
Iva Gudernova
DKDeborah Krakow
Deborah Krakow
Disrupting the PTH/PTHrP-SIK3 pathway impairs degradation of DEPTOR, affects mTOR signaling, and leads to abnormalities in skeletal development.

7 April 2016 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
CKCaroline Y. Kuo
Caroline Y. Kuo
DKDonald Kohn
Donald Kohn

18 August 2022 in Blood
Verified
Journal Article
Open access
PDF file
GCGeoffrey D. E. Cuvelier
Geoffrey D. E. Cuvelier
BLBrent R. Logan
Brent R. Logan
SPSusan E. Prockop
Susan E. Prockop
RBRebecca H. Buckley
Rebecca H. Buckley
CKCaroline Y. Kuo
Caroline Y. Kuo
DKDonald Kohn
Donald Kohn
Adenosine deaminase (ADA) deficiency causes ∼13% of cases of severe combined immune deficiency (SCID). Treatments include enzyme replacement therapy (ERT), hematopoietic cell transplant (HCT), and gene therapy (GT). We evaluated 131 patients with ADA-SCID diagnosed between 1982 and 2017 who were enrolled in the Primary Immune Deficiency Treatment Consortium SCID studies. Baseline clinical, immunologic, genetic characteristics, and treatment outcomes were analyzed. First definitive cellular therapy (FDCT) included 56 receiving HCT without preceding ERT (HCT); 31 HCT preceded by ERT (ERT-HCT); and 33 GT preceded by ERT (ERT-GT). Five-year event-free survival (EFS, alive, no need for further ERT or cellular therapy) was 49.5% (HCT), 73% (ERT-HCT), and 75.3% (ERT-GT; P < .01). Overall survival (OS) at 5 years after FDCT was 72.5% (HCT), 79.6% (ERT-HCT), and 100% (ERT-GT; P = .01). Five-year OS was superior for patients undergoing HCT at <3.5 months of age (91.6% vs 68% if ≥3.5 months, P = .02). Active infection at the time of HCT (regardless of ERT) decreased 5-year EFS (33.1% vs 68.2%, P < .01) and OS (64.7% vs 82.3%, P = .02). Five-year EFS (90.5%) and OS (100%) were best for matched sibling and matched family donors (MSD/MFD). For patients treated after the year 2000 and without active infection at the time of FDCT, no difference in 5-year EFS or OS was found between HCT using a variety of transplant approaches and ERT-GT. This suggests alternative donor HCT may be considered when MSD/MFD HCT and GT are not available, particularly when newborn screening identifies patients with ADA-SCID soon after birth and before the onset of infections. This trial was registered at www.clinicaltrials.gov as #NCT01186913 and #NCT01346150.

19 November 2020 in AIDS Care
Verified
Journal Article
Closed access
LCLucie Cluver
Lucie Cluver
JDJenny Doubt
Jenny Doubt
TAThe Teen Advisory Groups South Africa
The Teen Advisory Groups South Africa
IWInge Wessels
Inge Wessels
CACarine Asnong
Carine Asnong
MTMildred Thabeng
Mildred Thabeng
Whilst the HIV response has made significant progress in increasing representation of adults affected by HIV, the meaningful inclusion of children and adolescents has lagged. But this may be a pivotal moment of change. We report on a decade of conducting adolescent advisory groups in South Africa, to reflect on youth advisory processes. Data was collected from 2008 to 2018 from adolescent advisors (n = 60) and researchers (n = 25), and included feedback sessions, social media, anonymous “post-boxes” and interviews. Findings include the value of adolescent involvement in multiple stages of research co-creation and engagement in policy processes, the need for a safe environment and supporting adolescents living in extreme vulnerability. We also discuss the reconfiguring of power and personal relationships, and logistical and financial needs of adolescent advisory groups. Findings suggest that adolescent co-creation of research is feasible, even with very vulnerable adolescents, although ethical considerations need to be carefully addressed. Benefits include increased methodological rigour, enhanced adolescent acceptability of research and the recalibration of research dynamics for the empowerment of their target beneficiaries. Future studies could benefit from meaningfully involving adolescents through youth advisory groups.

2 September 2020 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
CKCaroline Y. Kuo
Caroline Y. Kuo
EGElizabeth Garabedian
Elizabeth Garabedian
JPJennifer Puck
Jennifer Puck
MCMorton J. Cowan
Morton J. Cowan
KSKathleen E. Sullivan
Kathleen E. Sullivan
DKDonald B. Kohn
Donald B. Kohn